Registered title, quoted from ClinicalTrials.gov
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Peking University Shenzhen Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07374614, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Diagnosis: Histologically or cytologically confirmed advanced lung adenocarcinoma.
Inclusion criterion 2
Wrong Diagnosis: Active malignancy of other histological types (excluding treated basal cell carcinoma, etc.).
Exclusion criterion 2
Pregnancy: Pregnant or breastfeeding women.
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07374614, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Population: Male or female patients aged ≥18 years.
- Diagnosis: Histologically or cytologically confirmed advanced lung adenocarcinoma.
- Molecular Status: Documentation of ALK rearrangement confirmed by a validated test (e.g., NGS, IHC, FISH).
- Prior Therapy: Prior treatment with lorlatinib (in any line of therapy), with documented disease progression or intolerance.
- Current Therapy: Initiated treatment with iruplinalkib in the real-world setting.
- Measurability: Presence of at least one evaluable lesion (measurable or non-measurable) for response assessment.
- Data Availability: availability of key clinical data (baseline characteristics, treatment history, and follow-up outcomes).
Exclusion Criteria:
- Lack of Exposure: Patients who never actually received iruplinalkib or took only a trivial amount (e.g., < 1 week/cycle) before withdrawal for non-medical reasons.
- Wrong Diagnosis: Active malignancy of other histological types (excluding treated basal cell carcinoma, etc.).
- Confounding: Participation in another interventional clinical trial involving an investigational anti-tumor drug concurrently.
- Pregnancy: Pregnant or breastfeeding women.
- Data Quality: Missing critical medical records that preclude assessment of primary endpoints (e.g., unknown start date, unknown prior therapy).
Quoted from ClinicalTrials.gov, NCT07374614, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07374614, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.